Brief: Medicenna Therapeutics Expect To Complete IND Enabling Studies For MDNA109 Superkine Platform By Q1
15/05/2020 12:55
May 15 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA THERAPEUTICS - END OF PHASE 2 MEETING PACKAGE
FOR
MDNA55 TO BE SUBMITTED IN Q2 2020
* MEDICENNA THERAPEUTICS - EXPECT TO COMPLETE IND ENABLING
STUDIES
FOR MDNA109 SUPERKINE PLATFORM BY Q1 OF CALENDAR YEAR 2021
Source text for Eikon: ID:nPnbjb0vwa
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results